Compare Pfizer with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs NOVARTIS - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER NOVARTIS PFIZER/
NOVARTIS
 
P/E (TTM) x 33.4 512.7 6.5% View Chart
P/BV x 5.6 29.7 18.8% View Chart
Dividend Yield % 0.6 1.5 39.6%  

Financials

 PFIZER   NOVARTIS
EQUITY SHARE DATA
    PFIZER
Mar-18
NOVARTIS
Mar-18
PFIZER/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs2,365758 312.0%   
Low Rs1,625579 280.7%   
Sales per share (Unadj.) Rs430.3228.4 188.4%  
Earnings per share (Unadj.) Rs78.731.7 248.0%  
Cash flow per share (Unadj.) Rs93.232.8 284.4%  
Dividends per share (Unadj.) Rs20.0010.00 200.0%  
Dividend yield (eoy) %1.01.5 67.0%  
Book value per share (Unadj.) Rs586.5297.1 197.4%  
Shares outstanding (eoy) m45.7524.69 185.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.62.9 158.4%   
Avg P/E ratio x25.321.1 120.3%  
P/CF ratio (eoy) x21.420.4 104.9%  
Price / Book Value ratio x3.42.2 151.2%  
Dividend payout %25.431.5 80.7%   
Avg Mkt Cap Rs m91,27116,505 553.0%   
No. of employees `0002.60.7 393.7%   
Total wages/salary Rs m3,1431,445 217.5%   
Avg. sales/employee Rs Th7,484.88,441.3 88.7%   
Avg. wages/employee Rs Th1,195.02,163.6 55.2%   
Avg. net profit/employee Rs Th1,369.11,173.1 116.7%   
INCOME DATA
Net Sales Rs m19,6855,639 349.1%  
Other income Rs m1,1431,718 66.5%   
Total revenues Rs m20,8287,357 283.1%   
Gross profit Rs m5,003-63 -8,004.6%  
Depreciation Rs m66325 2,618.6%   
Interest Rs m455 7.6%   
Profit before tax Rs m5,4791,575 347.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,878792 237.3%   
Profit after tax Rs m3,601784 459.5%  
Gross profit margin %25.4-1.1 -2,292.9%  
Effective tax rate %34.350.3 68.2%   
Net profit margin %18.313.9 131.6%  
BALANCE SHEET DATA
Current assets Rs m24,1679,522 253.8%   
Current liabilities Rs m9,5443,296 289.6%   
Net working cap to sales %74.3110.4 67.3%  
Current ratio x2.52.9 87.7%  
Inventory Days Days5537 150.4%  
Debtors Days Days2928 101.0%  
Net fixed assets Rs m9,51446 20,681.7%   
Share capital Rs m458123 370.7%   
"Free" reserves Rs m26,3757,213 365.7%   
Net worth Rs m26,8327,336 365.7%   
Long term debt Rs m250-   
Total assets Rs m36,90011,105 332.3%  
Interest coverage x1,305.529.5 4,427.9%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 105.1%   
Return on assets %9.87.6 129.3%  
Return on equity %13.410.7 125.6%  
Return on capital %20.422.2 91.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2261 37.0%   
Fx outflow Rs m1,4893,630 41.0%   
Net fx Rs m-1,466-3,570 41.1%   
CASH FLOW
From Operations Rs m3,3181,610 206.1%  
From Investments Rs m-2,383687 -346.9%  
From Financial Activity Rs m-1,104-2,677 41.2%  
Net Cashflow Rs m-169-380 44.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 4.9 1.6 306.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 21.5 110.2%  
Shareholders   85,207 41,647 204.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 20, 2019 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS